Vetoquinol SA (EPA:VETO)

France flag France · Delayed Price · Currency is EUR
80.50
+0.50 (0.63%)
Apr 28, 2026, 5:35 PM CET
9.97%
Market Cap 949.55M
Revenue (ttm) 525.70M
Net Income (ttm) 57.30M
Shares Out 11.80M
EPS (ttm) n/a
PE Ratio 16.57
Forward PE 15.34
Dividend 0.93 (1.16%)
Ex-Dividend Date Jun 4, 2025
Volume 2,828
Average Volume 2,139
Open 80.10
Previous Close 80.00
Day's Range 79.20 - 81.30
52-Week Range 68.70 - 91.50
Beta 0.95
RSI 50.40
Earnings Date Sep 11, 2026

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA. [Read more]

Sector Healthcare
Founded 1933
Employees 2,497
Stock Exchange Euronext Paris
Ticker Symbol VETO
Full Company Profile

Financial Performance

In 2025, Vetoquinol's revenue was 525.70 million, a decrease of -2.50% compared to the previous year's 539.20 million. Earnings were 57.30 million, a decrease of -2.36%.

Financial Statements

News

There is no news available yet.